Reps will tout new evidence that Fosamax increases bone density better than Actonel

December 2004

Reps will tout new evidence that Fosamax increases bone density better than Actonel in postmenopausal women.

But this is only part of the story.

It's true that a new study suggests Fosamax (alendronate) increases bone density of the hip by 3.4% in one year. This is compared to only 2.1% for Actonel (risedronate).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote